Last Updated: November 16, 2026

Drug Sales Trends for RESTASIS OP

« Back to Dashboard


Drug Sales Revenue Trends for RESTASIS OP
Drug Units Sold Trends for RESTASIS OP

RESTASIS OP Market Analysis, Sales Forecast, Patent Exclusivity and Generic Risk

Last updated: September 7, 2026

RESTASIS OP, AbbVie’s cyclosporine ophthalmic emulsion 0.05%, is a mature dry-eye product with substantial historical sales but limited long-term growth potential. U.S. revenue peaked before generic competition and declined after FDA-approved generic cyclosporine ophthalmic emulsion products entered the market. Base-case global branded sales are estimated to decline from approximately $300 million in 2024 to $150 million-$190 million by 2029, subject to pricing, formulary access, and generic substitution.

What is RESTASIS OP and how does it work?

RESTASIS OP is the ophthalmic formulation of cyclosporine 0.05%, marketed as an emulsion for increasing tear production in patients whose tear production is presumed to be suppressed by ocular inflammation associated with keratoconjunctivitis sicca, commonly called dry eye disease.[1]

Product attribute RESTASIS OP
Active ingredient Cyclosporine
Strength 0.05%
Dosage form Sterile ophthalmic emulsion
Route Topical ocular
Usual administration One drop in each eye twice daily
Original developer Allergan
Current commercial owner AbbVie, following its acquisition of Allergan
U.S. approval FDA approved in 2003
Primary indication Increased tear production in patients with dry eye disease
U.S. reference product Restasis, NDA 050790

RESTASIS does not contain a corticosteroid. Its commercial positioning is based on chronic anti-inflammatory treatment rather than short-term symptomatic relief. The product is supplied in single-use vials, with multidose presentations also used in certain markets.

How large is the RESTASIS OP market?

The addressable market is the prescription dry-eye segment, which includes cyclosporine, lifitegrast, ophthalmic corticosteroids, artificial tears, punctal plugs, and newer prescription products.

The total global dry-eye treatment market is commonly estimated in the low-single-digit billions of dollars annually. Prescription products represent a smaller but higher-value segment. RESTASIS competes primarily with:

  • Xiidra, lifitegrast ophthalmic solution, marketed by Bausch + Lomb.
  • Cequa, cyclosporine ophthalmic solution 0.09%, marketed by Sun Pharma.
  • Vevye, cyclosporine ophthalmic solution 0.1%, marketed by Harrow.
  • Generic cyclosporine ophthalmic emulsion 0.05%.
  • Artificial tears and other nonprescription products.

RESTASIS remains commercially relevant because dry eye is chronic, recurrent, and frequently treated over multiple years. Its market position has weakened because the product is mature, generic alternatives are available, and newer products emphasize improved delivery, higher concentration, or preservative-free multidose systems.

What were historical RESTASIS sales?

AbbVie and Allergan reported RESTASIS revenue within pharmaceutical-product sales disclosures before the product became exposed to substantial generic competition. Reported figures varied by fiscal year and reporting presentation.

Period Approximate branded sales trend Principal commercial factor
2017-2018 Approximately $1.3 billion-$1.5 billion annually Strong U.S. prescription franchise
2019 Approximately $1.2 billion Generic litigation and competitive pressure
2020 Approximately $1.0 billion-$1.1 billion Declining market exclusivity and COVID-19 disruption
2021 Approximately $900 million-$1.0 billion Pre-generic erosion and pricing pressure
2022 onward Sharp decline expected FDA-approved generic competition

The historical peak is not a reliable basis for current valuation. The product's revenue profile changed materially after generic cyclosporine ophthalmic emulsion approvals.

AbbVie has not consistently reported RESTASIS as a separately disclosed product in later financial filings. That limits the precision of current sales estimates and requires a bottom-up model based on prescription volume, net price, payer mix, and generic substitution.

What are the RESTASIS OP sales projections through 2029?

The following forecast is an analyst scenario model, not AbbVie guidance. It assumes that the reference product remains available in the United States, generic substitution continues, and no material new indication is approved.

Year Bear case Base case Bull case
2024 $250 million $325 million $400 million
2025 $210 million $290 million $370 million
2026 $180 million $260 million $345 million
2027 $155 million $235 million $325 million
2028 $135 million $210 million $305 million
2029 $115 million $185 million $285 million

These figures represent estimated worldwide branded RESTASIS sales, including the U.S. and selected international markets. They exclude generic cyclosporine revenue.

Base-case assumptions

The base case uses the following assumptions:

  1. U.S. branded volume declines by approximately 8%-12% annually.
  2. Net price declines by approximately 3%-5% annually because of rebates and payer restrictions.
  3. Generic cyclosporine captures approximately 55%-70% of eligible U.S. prescriptions by 2029.
  4. International sales decline more slowly because generic uptake and reimbursement systems differ by country.
  5. Xiidra, Cequa, and Vevye retain share in clinically differentiated or specialty-prescribing channels.

Under these assumptions, branded RESTASIS revenue falls approximately 40%-45% from the 2024 base estimate by 2029.

When did RESTASIS lose market exclusivity?

RESTASIS experienced a prolonged period of patent litigation before generic products reached the U.S. market. The most important commercial event was the FDA approval of generic cyclosporine ophthalmic emulsion 0.05% products in 2022.

Mylan Pharmaceuticals, now part of Viatris, received FDA approval for a generic version of Restasis in 2022. The approval followed years of litigation involving Allergan’s Restasis patents and patent-listing strategy.[2][3]

The market-exclusivity timeline is summarized below.

Event Date or period Commercial effect
FDA approval of Restasis 2003 Established the reference product
Allergan patent litigation and patent-listing disputes 2014-2019 Delayed generic launch
Federal court decisions involving Restasis patents 2017-2019 Reduced certainty around patent barriers
FDA approval of first generic Restasis products 2022 Opened the U.S. market to generic substitution
Post-generic period 2022-present Branded price and volume erosion

The principal loss of practical exclusivity occurred when FDA-approved generic products became commercially available, rather than on the earliest expiration date of every listed patent.

What patents protect RESTASIS OP?

RESTASIS has been protected by patents covering the cyclosporine ophthalmic emulsion, formulation characteristics, and related pharmaceutical compositions. The patent estate included patents listed in the FDA Orange Book and patents asserted in federal litigation.

Key patent families associated with Restasis litigation included:

Patent General subject matter Strategic relevance
U.S. Patent No. 6,982,089 Cyclosporine ophthalmic emulsion technology Early formulation protection
U.S. Patent No. 8,629,111 Ophthalmic cyclosporine compositions and related formulation claims Central later-stage patent protection
U.S. Patent No. 9,669,069 Cyclosporine ophthalmic emulsion and formulation claims Later Orange Book and litigation significance

Patent scope and enforceability must be assessed claim by claim. A patent expiration date does not guarantee market protection if claims are invalidated, disclaimed, not listed for a specific regulatory pathway, or avoided by a competing formulation.

Allergan’s strategy included patent litigation against generic applicants and litigation involving the Leahy-Smith America Invents Act’s inter partes review process. The U.S. Court of Appeals for the Federal Circuit rejected key aspects of Allergan’s effort to shield Restasis patents from inter partes review by transferring them to the Saint Regis Mohawk Tribe.[3]

What was the Paragraph IV challenge to RESTASIS?

Generic applicants filed Abbreviated New Drug Applications with Paragraph IV certifications challenging listed Restasis patents. Paragraph IV certifications assert that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

Allergan sued generic applicants, triggering the statutory 30-month stay for FDA approval under the Hatch-Waxman framework. The disputes involved:

  • Whether the generic formulations infringed Restasis patent claims.
  • Whether the asserted claims were obvious or anticipated.
  • Whether the patents were properly listed in the Orange Book.
  • Whether patent claims were enforceable after litigation conduct.
  • Whether generic manufacturers could proceed after court findings.

The patent litigation delayed generic entry but did not preserve the franchise indefinitely. Once generic approvals and commercial launches occurred, substitution risk became the primary driver of revenue decline.

What is the Orange Book status of RESTASIS?

Restasis is listed in the FDA Orange Book as a prescription ophthalmic drug. Orange Book-listed patents can impose regulatory approval delays for ANDA applicants when the reference sponsor brings timely patent litigation after a Paragraph IV notice.

The Orange Book is relevant to:

  • Patent listing and regulatory stay periods.
  • Generic certification strategy.
  • First-filer exclusivity analysis.
  • Authorized-generic planning.
  • Litigation timing and launch risk.

A listed patent does not establish that the patent is valid or enforceable. The FDA does not adjudicate patent validity. Those issues are determined through federal district court litigation, appellate review, or settlement arrangements.

Which companies are challenging or competing with RESTASIS?

The main competitive pressure comes from generic manufacturers and branded dry-eye companies.

Generic competitors

Viatris/Mylan was an early major generic entrant. Other generic manufacturers may enter through ANDAs or acquire commercial rights depending on manufacturing capacity, approval status, and market economics.

Generic cyclosporine competes primarily on:

  • Lower net price.
  • Pharmacy substitution.
  • Payer formulary preference.
  • Familiarity with the active ingredient.
  • Availability through retail and specialty pharmacies.

Branded competitors

Product Company Active ingredient Commercial differentiation
Xiidra Bausch + Lomb Lifitegrast 5% Different mechanism and branded positioning
Cequa Sun Pharma Cyclosporine 0.09% Higher concentration and nanomicellar delivery
Vevye Harrow Cyclosporine 0.1% Higher concentration and newer delivery system
Restasis AbbVie Cyclosporine 0.05% Established brand, clinical familiarity, broad historical use

RESTASIS retains advantages in physician familiarity and accumulated clinical experience. Its disadvantages include lower concentration than Cequa and Vevye, generic substitution, and reduced promotional priority compared with newer launches.

How does RESTASIS compare with Xiidra, Cequa and Vevye?

Factor RESTASIS Xiidra Cequa Vevye
Active ingredient Cyclosporine 0.05% Lifitegrast 5% Cyclosporine 0.09% Cyclosporine 0.1%
Drug class Calcineurin inhibitor LFA-1 antagonist Calcineurin inhibitor Calcineurin inhibitor
U.S. market status Mature, generic exposed Branded Branded, generic exposure varies Newer branded product
Main commercial strength Prescriber familiarity Different mechanism Higher concentration and delivery technology Higher concentration and newer formulation
Main commercial weakness Generic erosion Cost and tolerability considerations Smaller installed base Limited commercial history
Substitution risk High Moderate Moderate Low to moderate

RESTASIS is most vulnerable in price-sensitive plans and pharmacies with automatic generic substitution. It is less vulnerable where physicians maintain brand-specific prescribing preferences or where patients report better tolerability or persistence on the reference product.

What formulation patents protect RESTASIS and competing products?

Formulation protection is especially important for ophthalmic emulsions because the active ingredient alone is insufficient to reproduce the product’s commercial performance. Relevant technical attributes include:

  • Particle or droplet size.
  • Emulsion stability.
  • Surfactant composition.
  • Osmolality and pH.
  • Preservative status.
  • Container closure system.
  • Uniformity of cyclosporine delivery.
  • Single-dose versus multidose packaging.
  • Manufacturing controls for sterile ophthalmic products.

A generic applicant may obtain approval without reproducing every commercial feature of the branded product if its formulation satisfies FDA pharmaceutical-equivalence and bioequivalence requirements. Formulation patents can still create litigation risk when claims are broad enough to cover the generic composition or manufacturing process.

For investors and licensing parties, the strongest remaining barriers are generally product-specific formulation claims, manufacturing know-how, device or container patents, and regulatory data associated with newer delivery systems. RESTASIS’s core commercial barrier is weaker because the reference product has already faced successful generic competition.

What manufacturing and intellectual-property barriers remain?

Manufacturing cyclosporine ophthalmic emulsion requires control of sterile processing, emulsion stability, particle characteristics, filling, and container integrity. The active ingredient is not the main barrier. The principal operational barriers are:

  1. Sterile ophthalmic manufacturing capacity.
  2. Consistent emulsion performance at commercial scale.
  3. Stability over the labeled shelf life.
  4. Compliance with FDA current good manufacturing practice requirements.
  5. Demonstration of pharmaceutical equivalence and bioequivalence.
  6. Reliable single-dose or multidose packaging.

These barriers can limit the number of commercially viable suppliers even after patent expiry. They generally do not support the historical branded price premium once multiple FDA-approved products are available.

What regulatory status does RESTASIS have?

RESTASIS is an FDA-approved prescription drug under NDA 050790. The FDA label identifies cyclosporine ophthalmic emulsion 0.05% for increasing tear production in patients with dry eye disease associated with ocular inflammation.[1]

The product is not a biologic, so biosimilar legislation does not apply. Competitive products are approved through the generic-drug pathway or through separate 505(b)(2) or NDA pathways, depending on the product’s formulation, clinical data, and regulatory strategy.

No biosimilar risk exists for RESTASIS. The relevant competitive risks are generic substitution and branded reformulation.

What generic launch scenarios exist for RESTASIS?

Downside scenario

Generic products obtain broad formulary preference, and branded RESTASIS loses most pharmacy-level substitutions. U.S. branded revenue falls below $100 million by 2029. AbbVie maintains limited revenue through residual brand loyalty and international markets.

Base scenario

Generic penetration increases steadily, but some ophthalmologists continue to prescribe branded RESTASIS for established patients. AbbVie preserves a $150 million-$190 million global branded business by 2029.

Upside scenario

Generic supply interruptions, payer carve-outs, physician preference, or successful lifecycle management slow substitution. Branded revenue remains near $250 million-$300 million by 2029. This outcome requires persistent brand differentiation or favorable contracting.

The most probable scenario is continued decline with a residual branded franchise rather than immediate disappearance.

What licensing deals affect RESTASIS?

The principal transaction affecting RESTASIS was AbbVie’s acquisition of Allergan, completed in 2020. The transaction transferred Allergan’s ophthalmology portfolio, including Restasis, to AbbVie.[4]

No separate licensing transaction is required to explain the current commercial ownership of the product. Future value may arise from:

  • Authorized-generic arrangements.
  • Regional commercialization licenses.
  • Reformulated cyclosporine products.
  • Combination products for dry eye and ocular inflammation.
  • Manufacturing or supply agreements.

The value of a standalone RESTASIS license is constrained by generic competition. A transaction involving the brand alone would likely require low fixed consideration and performance-based economics tied to retained prescriptions, regional rights, or manufacturing advantages.

What litigation and settlement risks affect RESTASIS?

The most material historical litigation involved Allergan’s patent assertions against generic manufacturers and its attempt to use tribal sovereign immunity to limit inter partes review. The Federal Circuit held that tribal sovereign immunity did not prevent the Patent Trial and Appeal Board from proceeding with inter partes review of the Restasis patents.[3]

Current commercial litigation risk is more likely to involve:

  • Patent infringement claims against later generic entrants.
  • Product liability or manufacturing claims.
  • Antitrust allegations concerning patent listing or settlement conduct.
  • False advertising involving comparative dry-eye claims.
  • Contract disputes involving authorized generics or supply arrangements.

A future settlement could delay a particular generic launch but would have limited value if multiple approved suppliers already compete in the market.

What is the geographic coverage of RESTASIS?

The United States remains the largest commercial market for RESTASIS. International sales are affected by:

  • National marketing authorizations.
  • Local patent status.
  • Reimbursement and tender systems.
  • Reference pricing.
  • Local generic approvals.
  • Import and distribution requirements.
  • Different standards for ophthalmic bioequivalence.

The U.S. decline is expected to be faster than in some international markets because U.S. pharmacy substitution can rapidly redirect prescriptions to lower-priced generics. International revenue may therefore represent a larger percentage of total branded RESTASIS sales over time even as absolute sales decline.

How strong is the RESTASIS patent estate?

The patent estate was strong enough to delay generic entry and support extensive litigation, but it is no longer strong enough to preserve broad commercial exclusivity in the United States.

Patent-estate factor Assessment
Historical ability to delay generics High
Current U.S. exclusivity value Low to moderate
Formulation complexity Moderate
Generic substitution exposure High
Biosimilar risk None
Manufacturing barrier Moderate
Long-term growth potential Low
Residual brand value Moderate

The most defensible value is in brand recognition, physician familiarity, patient continuity, and commercial infrastructure. The weakest value is the ability to sustain premium pricing against approved generic cyclosporine.

What revenue exposure does RESTASIS create for AbbVie?

RESTASIS is no longer a major driver of AbbVie’s consolidated revenue compared with immunology, oncology, neuroscience, and aesthetics products. Its decline has limited effect on AbbVie’s overall financial profile, but it remains relevant for:

  • Ophthalmology portfolio strategy.
  • Sales-force allocation.
  • Contracting leverage.
  • Brand-to-generic conversion management.
  • Product-line profitability.
  • Potential authorized-generic economics.

A residual $185 million in 2029 sales would be commercially meaningful as a specialty product but immaterial relative to AbbVie’s total revenue base.

Key Takeaways

  • RESTASIS OP is cyclosporine ophthalmic emulsion 0.05%, approved by the FDA in 2003.
  • Historical annual sales reached approximately $1 billion or more before generic competition.
  • FDA-approved generic Restasis products entered the U.S. market in 2022.
  • Base-case branded global sales are estimated at approximately $325 million in 2024 and $185 million in 2029.
  • The main risks are generic substitution, payer pressure, and competition from Xiidra, Cequa, Vevye, and other dry-eye therapies.
  • RESTASIS has no biosimilar risk because it is a small-molecule ophthalmic drug, not a biologic.
  • The patent estate was historically effective but has limited remaining ability to protect broad U.S. branded revenue.
  • The product remains commercially viable as a residual brand, but long-term growth depends on brand loyalty, contracting, international markets, and lifecycle-management initiatives.

FAQs About RESTASIS OP Sales, Patents and Competition

What is the generic name for RESTASIS OP?

The generic name is cyclosporine ophthalmic emulsion 0.05%.

Is RESTASIS still protected by patents?

RESTASIS-related patents have supported extensive litigation, but FDA-approved generic products have entered the U.S. market. Patent protection no longer prevents broad generic competition.

Does RESTASIS have biosimilars?

No. RESTASIS is a small-molecule ophthalmic drug. Its competitors are generic or separately approved ophthalmic products, not biosimilars.

Which is stronger commercially, RESTASIS or Xiidra?

RESTASIS has greater historical brand recognition and a larger installed base. Xiidra has less direct exposure to cyclosporine generic substitution but remains subject to branded pricing and payer competition.

Will RESTASIS sales reach zero after generic entry?

No. A residual branded market is likely to remain because of physician preference, patient continuity, international sales, formulary exceptions, and prescriptions that are not automatically substituted.

References

  1. U.S. Food and Drug Administration. (2023). Restasis (cyclosporine ophthalmic emulsion) prescribing information.
  2. U.S. Food and Drug Administration. (2022). FDA approves first generic of Restasis to treat dry eye.
  3. Allergan, Inc. v. Saint Regis Mohawk Tribe, 899 F.3d 1325 (Fed. Cir. 2018).
  4. AbbVie Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.